Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus

NCT ID: NCT00668330

Last Updated: 2012-02-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-04-30
• Study Completion Date: 2009-05-31

Brief Summary

The primary aim of the present study was to investigate the prevalence of low bone mineral density (BMD) and vertebral fractures, as determined by a standardized assessment, and to elucidate the role of bone qualities, including micro-architecture, bone remodeling, bone turnover, mineralization and inflammation on bone density and prevalent vertebral fractures in a large population of systemic lupus erythematosus (SLE) patients.

The secondary aim of the study is to evaluate the following parameters in women with steroid induced OP (SIOP) before and after 1 year of treatment using:

1. The changes in BMD using dual energy X-ray absorptiometry (DXA)

2. Bone mineralization and architecture in-vivo using a newly available high-resolution human micro-computed tomography (ExtremCT), which can provide us with new insights into how the degree and distribution of mineralization are affected by long-term oral Ibandronate treatment.

3. Changes in perfusion and marrow edema before and after treatment of Ibandronate using dynamic Magnetic Resonance Imaging (MRI) in these patients with SIOP.

4. The investigators prospectively evaluate the correlation between the changes in brachial arterial endothelial function and lumbar spine BMD in female lupus patients over the period of 1 year.

Detailed Description

In the first part of the study, 150 consecutive patients with a diagnosis of SLE were included in the study. All patients fulfilled the American College of Rheumatology (ACR) revised criteria for the classification of SLE and provided written informed consent. Data collected at the time of study inclusion were age, disease duration, race, menstrual status, age at menopause, periods of amenorrhea, family history of osteoporosis, ultraviolet (UV) light intolerance, sunshine avoidance, use of sunscreens in the previous year, calculated mean daily dietary calcium intake in the last 3 months, history of (non)vertebral fractures after the age of 25 years, comorbidity, alcohol and tobacco intake, and exercise status.Body weight, height, and body mass index (BMI) were assessed. Disease activity was scored using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 54. Accumulated organ damage was assessed with the SLICC/ ACR damage index (DI) 55. A modified DI score was derived as the DI score excluding osteoporotic fractures as a damage item.BMD measurements of the hip (total hip and femoral neck) and the lumbar spine (L1-4; anteroposterior view) as well as lateral radiographs of the thoracic and lumbar spine (T5-L4)were performed. The prevalence of low BMD and vertebral fractures will be assessed.

In the second part of the study, 40 female SLE patients with steroid induced osteopenia will be enrolled in a 12-month, randomized, parallel-group, controlled study. Patients will receive either oral Ibandronate 150 mg once monthly plus daily alfacalcidol (0.001 mg) or placebo ibandronate once monthly plus daily alfacalcidol(0.001mg).In addition, the intake of dietary calcium will estimate by a questionnaire on the screening visit. All patients will receive a daily calcium supplement(500 mg).

Primary outcome is the improvement of bone mineral density measured by DEXA.

Secondary outcome includes:

1. Evaluation of the changes in bone mineralization and architecture measured by Xtreme CT.

2. Evaluation of the changes in perfusion and marrow edema using MRI.

3. Anti-proliferative and anti-inflammatory action of alfacalcidol using serum level of interleukin-6 (IL-6), transforming growth factor-beta-1, angiotensin-II, as well as urinary levels of TGF and monocyte chemoattractant protein-1 (MCP-1).

Conditions

Systemic Lupus Erythematosus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ibandronate+alfacalcidol+calcium

Bonviva

Group Type: ACTIVE_COMPARATOR

Ibandronate+alfacalcidol+calcium

Intervention Type: DRUG

Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium

placebo ibandronate+alfacalcidol+calcium

Intervention Type: DRUG

placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium

Placebo ibandronate+alfacalcidol+calcium

Group Type: ACTIVE_COMPARATOR

Ibandronate+alfacalcidol+calcium

Intervention Type: DRUG

Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium

placebo ibandronate+alfacalcidol+calcium

Intervention Type: DRUG

placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium

Interventions

Ibandronate+alfacalcidol+calcium

Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium

Intervention Type: DRUG

placebo ibandronate+alfacalcidol+calcium

placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium

Intervention Type: DRUG

Other Intervention Names

Bonviva; placebo Bonviva

Eligibility Criteria

Inclusion Criteria

• Fulfilled the ACR revised criteria for the classification of SLE
• Provided written informed consent for their participation

Part II

• Have low BMD (T socre < -1 S.D. at the lumbar spine (L1-L4) or total hip) induced by the long-term administration of high-dose corticosteroids.
• Had been receiving chronic uninterrupted corticosteroid therapy for at least 1 year or had received a corticosteroid dose of at least 5 mg/day.

Exclusion Criteria

• Hypocalcaemia, hypercalcaemia, Hypercalciuria, a creatinine clearance of less than 30 ml per minute.
• A history of nephrolithiasis during the previous five years.
• A history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis).
• Had or presence of primary hyperparathyroidism, hyperthyroidism, or hypothyroidism in the year before the study began.
• Had experienced any previous adverse reaction to bisphosphonate therapy (alendronate, fosamax, ibandronate).
• With uncontrolled active or recurrent peptic ulcer disease.
• Receiving therapy (within the last 6 months) known to affect bone metabolism, including:hormone-replacement agents, calcitonin, active vitamin D3 analogues, thiazide diuretics,treatment with bisphosphonates,fluoride treatment within the last 12 mons or for a total duration of 2 years; contraindications to calcium or vitamin D therapy.
• Pregnant or breastfeeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: lead

Responsible Party

Lai-Shan Tam

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Edmund K Li, MD

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

School of Pharmacy CUHK

Hong Kong, , China

Countries

China

References

Li EK, Zhu TY, Hung VY, Kwok AW, Lee VW, Lee KK, Griffith JF, Li M, Wong KC, Leung PC, Qin L, Tam LS. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther. 2010;12(5):R198. doi: 10.1186/ar3170. Epub 2010 Oct 22.

Reference Type: DERIVED

PMID: 20964867 (View on PubMed)

Other Identifiers

SLE-2007-007

Identifier Type: -

Identifier Source: org_study_id